Company intelligence / Profile preview
AprilBio Co., Ltd.
Chuncheon, Gangwon Province, South Koreaaprilbio.com ↗
- Ownership
- Public · 397030
- Development stage
- Phase 2
01
Overview
The company has developed APB-R3 (now EVO301), a long-acting injectable fusion protein designed to neutralize the IL-18 pathway for inflammation regulation. This product has been licensed to Evommune, which plans to initiate Phase 2 clinical trials in early 2025[5].
- Therapeutic areas
- OncologyRare DiseasesImmunology
- Modalities
- Antibody fragmentsFusion proteinsLong-acting recombinant protein pharmaceuticals
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Evommune, Inc. (licensed APB-R3/EVO301)[5]
Beyond the preview
Go deeper on AprilBio Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AprilBio Co., Ltd..